Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use

FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.